Clinical Trial Update: Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib in advanced anaplastic thyroid cancer and recurrent thyroid cancer has been terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-08-10